---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-019639"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:47:02.562555+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adial Pharmaceuticals regains Nasdaq minimum bid price compliance; highlights advanced AD04 partnering discussions

## Summary
- Received Nasdaq notice on Feb. 23, 2026 that closing bid price was ≥$1.00 for 10 consecutive business days (Feb. 6-20, 2026).
- Nasdaq confirmed compliance with Listing Rule 5550(a)(2) and closed the matter.
- CEO Cary Claiborne stated the company is engaged in advanced strategic partnering discussions for AD04.
- AD04 is a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder, moving toward Phase 3 program.

## SEC filing metadata
- accession: 0001213900-26-019639
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026019639/0001213900-26-019639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026019639/ea0278114-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-019639
- JSON: https://secwatch.observer/filing/0001213900-26-019639.json
- Plain text: https://secwatch.observer/filing/0001213900-26-019639.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.